MapLight Therapeutics (MPLT) Common Equity (2024 - 2025)
MapLight Therapeutics recorded quarterly Common Equity of $458.4 million in Q4 2025, up 267.18% quarter-over-quarter from -$274.2 million in Q3 2025, and up 336.73% year-over-year from $105.0 million in Q4 2024.
MapLight Therapeutics' Common Equity history runs 2 years deep, the most recent figure standing at $458.4 million for Q4 2025.
- In Q4 2025, Common Equity rose 336.73% year-over-year to $458.4 million; the TTM figure through Dec 2025 stood at $458.4 million (up 336.73% YoY), while the FY2025 annual figure was $458.4 million, up 336.73% from the prior year.
- Common Equity came in at $458.4 million for Q4 2025 at MapLight Therapeutics, up from -$274.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $458.4 million in Q4 2025 to a low of -$274.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.08 Bn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | 458.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 458.37 Mn |
| Sep 30, 2025 | -274.18 Mn |
| Dec 31, 2024 | -193.63 Mn |
| Sep 30, 2024 | -172.37 Mn |